Our study indicated that HDACis could significantly improve the cytotoxicity of cisplatin only in low ERCC1-expressing NSCLC cell lines without GOF p53 mutations based not only on chromatin structure alterations but also on p53-induced cell apoptosis. This evidence concerns the gene TP53 and non-small cell lung carcinoma.